Inspired by Nature.
Empowered by Technology.
Committed to Life.
Advancing Human-Relevant Systems to Reduce Reliance on Animal Models
Integrated • Predictive • Translational
Accelerating Smarter, More Human-Relevant Medicine
Our Operating
Model
NAMina Bio integrates human-relevant models, dynamic physiology systems, multi-omics, and AI-assisted analytics into structured translational workflows designed to improve the predictive value of preclinical research.
Rather than using individual technologies in isolation, we organize them into coherent experimental architectures aligned to specific biological and translational questions.
Aligned with the shift toward human-relevant methodologies and New Approach Methodologies (NAMs), we support more predictive and clinically relevant preclinical research.
NAMina Bio executes translational programs through a phased model that combines ecosystem integration with scalable experimental deployment.
Our Translational
Collaboration
Network
NAMina Bio operates as a translational architecture hub, aligning advanced NAM technologies, biotech innovators, pharmaceutical partners, and academic collaborators within structured preclinical programs.
Through phased activation and curated partnerships, we integrate human-relevant platforms into high-value scientific environments to support more predictive, ethical, and decision-ready drug development.
Biotech & Pharma
NAMina Bio supports biotech and pharmaceutical partners with structured, human-relevant preclinical programs aligned with New Approach Methodologies (NAMs).
We integrate 3D systems, microphysiological platforms, and AI-assisted analytics to strengthen translational decision-making and reduce development risk.
Technology Partners
We collaborate with platform innovators in 3D culture, organ-on-chip, synthetic matrices, and AI analytics to embed emerging technologies within structured translational research programs.
NAMina provides scientific integration, pilot validation, and ecosystem positioning within high-density biotech environments.
Academic Collaborators
NAMina Bio partners with universities and research institutes to translate discovery science into human-relevant preclinical applications.
We support joint grants, co-developed disease models, and translational research initiatives aligned with NAM frameworks.
Our Technology Partners
Collaborating with global innovators to advance predictive, human-relevant preclinical systems.
NAMina Bio works with leading providers in 3D bioprinting, synthetic matrices, organ-on-chip platforms, sequencing, and AI-driven analytics to structure integrated translational programs across disease areas.
Together, we enable more predictive preclinical workflows that reduce reliance on low-translational animal models while strengthening human-relevant data generation.
Explore Our Technology Network →
Research & Innovation Focus
Next-Generation Human-Relevant Models
NAMina Bio develops advanced microphysiological and 3D tumor platforms designed to model complex human disease biology under clinically relevant conditions.
Glioma Microphysiological Systems
We are developing dynamic glioma models incorporating oxygen gradients, neurovascular signaling, and therapy response dynamics to support translational oncology research.
PDAC Tumoroid Platforms
Leveraging 3D bioprinting and defined ECM systems, we engineer pancreatic ductal adenocarcinoma models that recapitulate tissue stiffness, adaptive resistance, and microenvironmental conditioning.
AI-Powered Translational Intelligence
We integrate molecular, phenotypic, and clinical datasets within structured computational frameworks to support predictive modeling and biomarker-informed study design.